{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:25:34Z","timestamp":1786465534632,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02953-5","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:00Z","timestamp":1786460520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B\/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515)"],"prefix":"10.1038","volume":"11","author":[{"given":"Qingyun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiran","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CHANCE2515 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Nan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ran","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Guo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Yang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Yong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hao","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Shi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2953_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA. Cancer J. Clin."},{"key":"2953_CR2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","volume":"18","author":"G Lau","year":"2024","unstructured":"Lau, G. et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatol. Int. 18, 1661\u20131683 (2024).","journal-title":"Hepatol. Int."},{"key":"2953_CR3","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"2953_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315\u2013374 (2025).","journal-title":"J. Hepatol."},{"key":"2953_CR5","doi-asserted-by":"publisher","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update. J. Hepatol. S0168-8278 02571\u201302571. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020 (2025).","DOI":"10.1016\/j.jhep.2025.10.020"},{"key":"2953_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.29883","volume":"68","author":"MH Hyun","year":"2018","unstructured":"Hyun, M. H. et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology 68, 977\u2013993 (2018).","journal-title":"Hepatology"},{"key":"2953_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41575-025-01143-y","volume":"23","author":"AK Malik","year":"2026","unstructured":"Malik, A. K. et al. Improving surgical treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 23, 208\u2013226 (2026).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2953_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"J-L Raoul","year":"2019","unstructured":"Raoul, J.-L. et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev. 72, 28\u201336 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"2953_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.14218\/JCTH.2016.00058","volume":"4","author":"A Schicho","year":"2016","unstructured":"Schicho, A. et al. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. J Clin Transl Hepatol 4, 288\u2013292 (2016).","journal-title":"J Clin Transl Hepatol"},{"key":"2953_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3748\/wjg.v24.i2.161","volume":"24","author":"A Facciorusso","year":"2018","unstructured":"Facciorusso, A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J. Gastroenterol. 24, 161\u2013169 (2018).","journal-title":"World J. Gastroenterol."},{"key":"2953_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/15685551.2022.2164445","volume":"26","author":"H Zhou","year":"2023","unstructured":"Zhou, H. et al. Temperature sensitive nanogels for real-time imaging during transcatheter arterial embolization. Des. Monomers Polym. 26, 31\u201344 (2023).","journal-title":"Des. Monomers Polym."},{"key":"2953_CR12","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.21037\/tau-24-215","volume":"13","author":"F Lin","year":"2024","unstructured":"Lin, F. et al. Retrospective observation of the early efficacy and safety of temperature-sensitive liquid embolic agent combined with polyvinyl alcohol microspheres for prostatic artery embolization in the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. Transl. Androl. Urol. 13, 1847\u20131858 (2024).","journal-title":"Transl. Androl. Urol."},{"key":"2953_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4103\/jcrt.jcrt_2250_24","volume":"21","author":"S Zhou","year":"2025","unstructured":"Zhou, S., Lin, Q., Zhong, J. & Chen, J. An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization. J. Cancer Res. Ther. 21, 504\u2013508 (2025).","journal-title":"J. Cancer Res. Ther."},{"key":"2953_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","volume":"103","author":"J Yang","year":"2018","unstructured":"Yang, J., Pi, C. & Wang, G. Inhibition of PI3K\/Akt\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed. Pharmacother. 103, 699\u2013707 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2953_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","volume":"42","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell 42, 535\u2013551.e8 (2024).","journal-title":"Cancer Cell"},{"key":"2953_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jhep.2020.05.028","volume":"73","author":"Y Pang","year":"2020","unstructured":"Pang, Y. et al. Peptide SMIM30 promotes HCC development by inducing SRC\/YES1 membrane anchoring and MAPK pathway activation. J. Hepatol. 73, 1155\u20131169 (2020).","journal-title":"J. Hepatol."},{"key":"2953_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174415","volume":"134","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. TSC\/mTORC1 mediates mTORC2\/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M. J. Clin. Invest. 134, e174415 (2024).","journal-title":"J. Clin. Invest."},{"key":"2953_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F., Jaccard, A., Romero, P., Yu, Y.-R. & Ho, P.-C. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2, 1001\u20131012 (2020).","journal-title":"Nat. Metab."},{"key":"2953_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10893-8","volume":"10","author":"M Hu","year":"2019","unstructured":"Hu, M. et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat. Commun. 10, 2993 (2019).","journal-title":"Nat. Commun."},{"key":"2953_CR20","doi-asserted-by":"publisher","first-page":"eabp8964","DOI":"10.1126\/science.abp8964","volume":"379","author":"TE Sutherland","year":"2023","unstructured":"Sutherland, T. E., Dyer, D. P. & Allen, J. E. The extracellular matrix and the immune system: A mutually dependent relationship. Science 379, eabp8964 (2023).","journal-title":"Science"},{"key":"2953_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduction Targeted Ther. 6, 412 (2021).","journal-title":"Signal Transduction Targeted Ther."},{"key":"2953_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.tim.2003.11.003","volume":"12","author":"A Roeder","year":"2004","unstructured":"Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M. & Korting, H. C. Toll-like receptors and innate antifungal responses. Trends Microbiol 12, 44\u201349 (2004).","journal-title":"Trends Microbiol"},{"key":"2953_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07738-2","volume":"16","author":"B Pan","year":"2025","unstructured":"Pan, B. et al. N-glycosylated LT\u03b2R increases the Th17\/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription. Cell Death Dis. 16, 421 (2025).","journal-title":"Cell Death Dis."},{"key":"2953_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1749","volume":"14","author":"G Jia","year":"2022","unstructured":"Jia, G. et al. Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 14, e1749 (2022).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"2953_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"K Malagari","year":"2009","unstructured":"Malagari, K. et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. CardioVasc. Interventional Radiol. 33, 541\u2013551 (2009).","journal-title":"CardioVasc. Interventional Radiol."},{"key":"2953_CR26","doi-asserted-by":"publisher","first-page":"102465","DOI":"10.1016\/j.nano.2021.102465","volume":"39","author":"AC Cortes","year":"2022","unstructured":"Cortes, A. C. et al. Effect of bead size and doxorubicin loading on tumor cellular injury after transarterial embolization and chemoembolization in a rat model of hepatocellular carcinoma. Nanomed. Nanotechnol. Biol. Med. 39, 102465 (2022).","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"2953_CR27","doi-asserted-by":"publisher","first-page":"20210594","DOI":"10.1259\/bjr.20210594","volume":"95","author":"L Beaton","year":"2021","unstructured":"Beaton, L. et al. Radiopaque drug-eluting embolisation beads as fiducial markers for stereotactic liver radiotherapy. Br. J. Radiol. 95, 20210594 (2021).","journal-title":"Br. J. Radiol."},{"key":"2953_CR28","doi-asserted-by":"publisher","first-page":"31353","DOI":"10.1021\/acsomega.3c09368","volume":"9","author":"JL Zhang","year":"2024","unstructured":"Zhang, J. L. et al. X-ray opaque polymer drug-eluting beads loaded with iodized oil: preparation and in vitro and in vivo evaluations. ACS Omega 9, 31353\u201331358 (2024).","journal-title":"ACS Omega"},{"key":"2953_CR29","first-page":"339","volume":"21","author":"Y-S Liu","year":"2020","unstructured":"Liu, Y.-S. et al. Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: a feasibility study. Bosnian J. Basic Med. 21, 339\u2013345 (2020).","journal-title":"Bosnian J. Basic Med."},{"key":"2953_CR30","doi-asserted-by":"publisher","first-page":"108966","DOI":"10.1016\/j.ejrad.2020.108966","volume":"126","author":"J Urbano","year":"2020","unstructured":"Urbano, J. et al. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. Eur. J. Radiol. 126, 108966 (2020).","journal-title":"Eur. J. Radiol."},{"key":"2953_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41392-025-02427-0","volume":"10","author":"K Wang","year":"2025","unstructured":"Wang, K. et al. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial. Signal Transduction Targeted Ther. 10, 328 (2025).","journal-title":"Signal Transduction Targeted Ther."},{"key":"2953_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1200\/JCO-25-01796","volume":"44","author":"H-D Zhu","year":"2026","unstructured":"Zhu, H.-D. et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005\/CARES-005): A Randomized Phase II Trial. J. Clin. Oncol. 44, 959\u2013969 (2026).","journal-title":"J. Clin. Oncol."},{"key":"2953_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405, 216\u2013232 (2025).","journal-title":"Lancet"},{"key":"2953_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrc.2017.105","volume":"18","author":"D Senft","year":"2017","unstructured":"Senft, D., Qi, J. & Ronai, Z. A. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer 18, 69\u201388 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2953_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02403-1","volume":"11","author":"Y Shi","year":"2025","unstructured":"Shi, Y., Zhang, H. & Miao, C. Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives. Cell Death Discovery 11, 123 (2025).","journal-title":"Cell Death Discovery"},{"key":"2953_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723\u2013750 (2018).","journal-title":"Hepatology"},{"key":"2953_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236 (2018).","journal-title":"J. Hepatol."},{"key":"2953_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet, J. M. & Lencioni, R. mRECIST for HCC: Performance and novel refinements. J. Hepatol. 72, 288\u2013306 (2020).","journal-title":"J. Hepatol."},{"key":"2953_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2953_CR40","doi-asserted-by":"publisher","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","volume":"96","author":"G Mathew","year":"2021","unstructured":"Mathew, G. et al. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int. J. Surg. 96, 106165 (2021).","journal-title":"Int. J. Surg."},{"key":"2953_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F-H Wang","year":"2023","unstructured":"Wang, F.-H. et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 44, 127\u2013172 (2023).","journal-title":"Cancer Commun."},{"key":"2953_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","volume":"56","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji, H. et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J. Gastroenterol. 56, 593\u2013619 (2021).","journal-title":"J. Gastroenterol."},{"key":"2953_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore, K. P. et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38, 258\u2013266 (2003).","journal-title":"Hepatology"},{"key":"2953_CR44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis, R., Baveno, V. I. & Faculty Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63, 743\u2013752 (2015).","journal-title":"J. Hepatol."},{"key":"2953_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jclinepi.2022.03.022","volume":"148","author":"A Drosdowsky","year":"2022","unstructured":"Drosdowsky, A. & Gough, K. The Charlson Comorbidity Index: problems with use in epidemiological research. J. Clin. Epidemiol. 148, 174\u2013177 (2022).","journal-title":"J. Clin. Epidemiol."},{"key":"2953_CR46","first-page":"779","volume":"14","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer 14, 779\u2013835 (2025).","journal-title":"Liver Cancer"},{"key":"2953_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","volume":"18","author":"J Shi","year":"2010","unstructured":"Shi, J. et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci. 18, 74\u201380 (2010).","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"2953_CR48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/hbsn.2019.10.07","volume":"9","author":"Z-H Chen","year":"2020","unstructured":"Chen, Z.-H. et al. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 9, 717\u2013728 (2020).","journal-title":"Hepatobiliary Surg Nutr."},{"key":"2953_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35\u201343 (2009).","journal-title":"Lancet Oncol."},{"key":"2953_CR50","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck, A. C. et al. Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 1, 1051 (2015).","journal-title":"JAMA Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02953-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02953-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02953-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:03Z","timestamp":1786460523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02953-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2953"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02953-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"329"}}